Partners

Factor works with strategic partners to develop and advance products based on our technologies to the clinic. Factor’s technologies have the potential to contribute to new therapeutic products, many of which will require testing in clinical trials. As a result, Factor collaborates with companies that have extensive experience in all stages of the therapeutic product development pipeline.

Pictured from left to right: Howard Federoff, M.D., Ph.D., CEO of Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX); Christopher Rohde, Ph.D., Co-Founder and Chief Technology Officer of Factor Bioscience Inc.; Gregory Fiore, M.D., Co-Founder and CEO of Exacis Biotherapeutics Inc.; Matt Angel, Ph.D., Co-Founder, Chairman, and CEO of Factor Bioscience Inc.

Acquired in 2021 by Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX), Novellus was founded by the Factor team to develop therapeutic products based on Factor's technologies. Novellus is focused on developing advanced mesenchymal stem cell ("MSC")-based therapies to treat a broad range of disease indications.

Founded in 2020 by the Factor team, Exacis is using Factor's technologies to develop advanced T-cell and NK-cell therapies to treat cancer.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. Brooklyn is using Factor's technologies to develop multiple next-generation cell and gene-editing therapies for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as rare genetic diseases.

CÚRAM is the Science Foundation Ireland Centre for Research in Medical Devices, based at the National University of Ireland, Galway. CÚRAM’s innovative approach incorporates biomaterials, drug delivery, cell-based technologies, glycosciences and device design to enhance, develop and validate both traditional and new combinational medical devices from molecular design stage to implant manufacturing. Factor is currently sponsoring multiple collaborative research projects at CÚRAM focused on next-generation mRNA and engineered cell therapies.

Erigen LLC was founded by the Factor team to provide cell and nucleic-acid research services, including the creation of custom cell and tissue disease models. For more information on Erigen’s capabilities and portfolio of services, contact: info@erigen.com.

Acquired in 2021 by Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX), Novellus was founded by the Factor team to develop therapeutic products based on Factor's technologies. Novellus is focused on developing advanced mesenchymal stem cell ("MSC")-based therapies to treat a broad range of disease indications.

Founded in 2020 by the Factor team, Exacis is using Factor's technologies to develop advanced T-cell and NK-cell therapies to treat cancer.

Brooklyn ImmunoTherapeutics, Inc. (Nasdaq: BTX) is focused on exploring the role that cytokine, gene editing, and cell therapy can have in treating patients with cancer, blood disorders, and monogenic diseases. Brooklyn is using Factor's technologies to develop multiple next-generation cell and gene-editing therapies for various indications, including acute respiratory distress syndrome, solid tumor indications, as well as rare genetic diseases.

CÚRAM is the Science Foundation Ireland Centre for Research in Medical Devices, based at the National University of Ireland, Galway. CÚRAM’s innovative approach incorporates biomaterials, drug delivery, cell-based technologies, glycosciences and device design to enhance, develop and validate both traditional and new combinational medical devices from molecular design stage to implant manufacturing. Factor is currently sponsoring multiple collaborative research projects at CÚRAM focused on next-generation mRNA and engineered cell therapies.

Erigen LLC was founded by the Factor team to provide cell and nucleic-acid research services, including the creation of custom cell and tissue disease models. For more information on Erigen’s capabilities and portfolio of services, contact: info@erigen.com.